1987
DOI: 10.1016/s0735-1097(87)80094-3
|View full text |Cite
|
Sign up to set email alerts
|

Noninvasive evaluation of the effect of timolol on left ventricular performance after myocardial infarction and the consequence for prognosis

Abstract: Left ventricular performance was evaluated noninvasively in 111 patients participating at one study center in the Norwegian Multicenter Study on Timolol After Myocardial Infarction. Systolic time intervals were measured in 55 patients treated with timolol and in 56 patients receiving placebo. Measurements were made before randomization, and after 1, 3 and 12 months of treatment. During the treatment period, the pre-ejection period/left ventricular ejection time ratio was significantly lower in the timolol-trea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
5
0

Year Published

1987
1987
2019
2019

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 21 publications
0
5
0
Order By: Relevance
“…The estimation of cardiac time intervals using PCG, SCG and ICG, investigated in this study, offers an opportunity to assess cardiac contractility which, in addition to the analysis of the other features of these signals, broadens the potential of SCG, PCG and ICG in the monitoring of cardiovascular performance. As these technologies yield themselves to wearable applications, they could be used outside of the hospital/clinical settings to detect the potential abnormalities and malfunctions of the cardiovascular system such as heart failure (Inan et al, 2018), hypovolemia (Tavakolian et al, 2014), and hypotension (Brubakk et al, 1987) or to validate cardiac resynchronization therapy (Marcus et al, 2007). Moreover, this technology can be used to monitor the improvement of cardiac performance in healthy individuals as a result of the adoption of a healthier and more active lifestyle.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The estimation of cardiac time intervals using PCG, SCG and ICG, investigated in this study, offers an opportunity to assess cardiac contractility which, in addition to the analysis of the other features of these signals, broadens the potential of SCG, PCG and ICG in the monitoring of cardiovascular performance. As these technologies yield themselves to wearable applications, they could be used outside of the hospital/clinical settings to detect the potential abnormalities and malfunctions of the cardiovascular system such as heart failure (Inan et al, 2018), hypovolemia (Tavakolian et al, 2014), and hypotension (Brubakk et al, 1987) or to validate cardiac resynchronization therapy (Marcus et al, 2007). Moreover, this technology can be used to monitor the improvement of cardiac performance in healthy individuals as a result of the adoption of a healthier and more active lifestyle.…”
Section: Discussionmentioning
confidence: 99%
“…Cardiac time intervals have clinical significance in mitral valve stenosis, coronary artery disease (Boudoulas, 1990; Reant et al, 2010), arterial hypertension (Brubakk et al, 1987), atrial fibrillation, hypovolemia and fluid responsiveness (Tavakolian et al, 2014), chronic myocardial disease (Reant et al, 2010) and in the assessment of left ventricular performance (Boudoulas, 1990; Reant et al, 2010). These intervals present a temporal description of the sequential phases of a cardiac cycle.…”
Section: Introductionmentioning
confidence: 99%
“…This mortality rate is independent of the number of involved vessels. 26 Brubakk et al 27 stated that in the 1st month after myocardial infarction, a PEP/LVET ratio above 0.42 indicates a decrease in the 6-year survival rate. According to Stack et al, 28 a high PEP/LVET ratio in resting conditions is related to LV function and the degree of coronary stenosis and the number of involved vessels.…”
Section: Discussionmentioning
confidence: 99%
“…The study was a subproject of the Norwegian Multicenter Study on timolol after myocardial infarction [1], The methods and follow up have been described in detail elsewhere [1,7,9].…”
Section: Patient Groupsmentioning
confidence: 99%
“…The findings of the study indicate that the length of the diastole is a prognostic factor with respect to survival after acute myocardial infarction and that timolol has a lengthening effect on diastole beyond the effect of reduced HR. ß-Blocker treatment reduces mortality and reinfarc tion after acute myocardial infarction [1][2][3][4].The mechanism of this favorable effect is still under debate [5,6] and may depend on several factors, including control of hypertension, anti-ischemic effect, antiarrhythmogenic properties and antiplatelet effect.The ß-adrenergic blocking agent timolol has been found to preserve left ventricular function better than pla cebo treatment in patients treated for 1 year after acute myocardial infarction [7], Increased diastolic time (DT) has been proposed as a beneficial effect of propranolol in patients with coronary artery disease [8].This study was performed in order to: (1) evaluate DT in relation to mortality after acute myocardial infarction, and (2) study the duration of the diastole in patients treated with timolol after acute myocardial infarction, compared both to a placebo-treated group of patients and to a normal group of individuals. …”
mentioning
confidence: 99%